These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
494 related articles for article (PubMed ID: 28434111)
1. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111 [TBL] [Abstract][Full Text] [Related]
2. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467 [TBL] [Abstract][Full Text] [Related]
3. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas. Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193 [TBL] [Abstract][Full Text] [Related]
4. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974 [TBL] [Abstract][Full Text] [Related]
5. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286 [TBL] [Abstract][Full Text] [Related]
6. Conventional Magnetic Resonance Features for Predicting 1p19q Codeletion Status of World Health Organization Grade II and III Diffuse Gliomas. Peng X; Yishuang C; Kaizhou Z; Xiao L; Ma C J Comput Assist Tomogr; 2019; 43(2):269-276. PubMed ID: 30371623 [TBL] [Abstract][Full Text] [Related]
7. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
8. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma. Liu Z; Zhang T; Jiang H; Xu W; Zhang J Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056 [TBL] [Abstract][Full Text] [Related]
9. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
10. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590 [TBL] [Abstract][Full Text] [Related]
11. Prediction of Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763 [TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era. Tom MC; Varra V; Leyrer CM; Park DY; Chao ST; Yu JS; Suh JH; Reddy CA; Balagamwala EH; Broughman JR; Kotagal KA; Vogelbaum MA; Barnett GH; Ahluwalia MS; Peereboom DM; Prayson RA; Stevens GHJ; Murphy ES Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1099-1105. PubMed ID: 31022510 [TBL] [Abstract][Full Text] [Related]
13. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas. Yang X; Lin Y; Xing Z; She D; Su Y; Cao D Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488 [TBL] [Abstract][Full Text] [Related]
14. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469 [TBL] [Abstract][Full Text] [Related]
15. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma. Karsy M; Guan J; Huang LE J Neurosurg; 2019 Jan; 130(1):56-66. PubMed ID: 29547090 [TBL] [Abstract][Full Text] [Related]
17. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348 [TBL] [Abstract][Full Text] [Related]
19. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient. Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266 [TBL] [Abstract][Full Text] [Related]
20. Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis. Hayashi S; Kitamura Y; Hirose Y; Yoshida K; Sasaki H J Neurooncol; 2017 Mar; 132(1):119-126. PubMed ID: 28025770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]